• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用脂质纳米颗粒进行CRISPR-Cas9和单纯疱疹病毒胸苷激酶自杀基因疗法的缺氧导向肿瘤靶向治疗。

Hypoxia-directed tumor targeting of CRISPR-Cas9 and HSV-TK suicide gene therapy using lipid nanoparticles.

作者信息

Davis Alicia, Morris Kevin V, Shevchenko Galina

机构信息

Center for Gene Therapy, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA.

Irell & Manella Graduate School of Biological Sciences, City of Hope, Duarte, CA 91010, USA.

出版信息

Mol Ther Methods Clin Dev. 2022 Mar 16;25:158-169. doi: 10.1016/j.omtm.2022.03.008. eCollection 2022 Jun 9.

DOI:10.1016/j.omtm.2022.03.008
PMID:35402634
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8971340/
Abstract

Hypoxia is a characteristic feature of solid tumors that contributes to tumor aggressiveness and is associated with resistance to cancer therapy. The hypoxia inducible factor-1 (HIF-1) transcription factor complex mediates hypoxia-specific gene expression by binding to hypoxia-responsive element (HRE) sequences within the promoter of target genes. HRE-driven expression of therapeutic cargo has been widely explored as a strategy to achieve cancer-specific gene expression. By utilizing this system, we achieve hypoxia-specific expression of two therapeutically relevant cargo elements: the herpes simplex virus thymidine kinase (HSV-tk) suicide gene and the CRISPR-Cas9 nuclease. Using an expression vector containing five copies of the HRE derived from the vascular endothelial growth factor gene, we are able to show high transgene expression in cells in a hypoxic environment, similar to levels achieved using the cytomegalovirus (CMV) and CBh promoters. Furthermore, we are able to deliver our therapeutic cargo to tumor cells with high efficiency using plasmid-packaged lipid nanoparticles (LNPs) to achieve specific killing of tumor cells in hypoxic conditions while maintaining tight regulation with no significant changes to cell viability in normoxia.

摘要

缺氧是实体瘤的一个特征,它有助于肿瘤的侵袭性,并与癌症治疗耐药性相关。缺氧诱导因子-1(HIF-1)转录因子复合物通过与靶基因启动子内的缺氧反应元件(HRE)序列结合来介导缺氧特异性基因表达。作为实现癌症特异性基因表达的一种策略,HRE驱动的治疗性载体表达已得到广泛探索。通过利用该系统,我们实现了两种治疗相关载体元件的缺氧特异性表达:单纯疱疹病毒胸苷激酶(HSV-tk)自杀基因和CRISPR-Cas9核酸酶。使用一个包含五个源自血管内皮生长因子基因的HRE拷贝的表达载体,我们能够在缺氧环境中的细胞中显示出高转基因表达,类似于使用巨细胞病毒(CMV)和CBh启动子所达到的水平。此外,我们能够使用质粒包装的脂质纳米颗粒(LNP)将我们的治疗性载体高效递送至肿瘤细胞,以在缺氧条件下实现肿瘤细胞的特异性杀伤,同时在常氧条件下保持严格调控,细胞活力无显著变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20dd/8971340/9bd2ad9da859/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20dd/8971340/a52bb17366a0/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20dd/8971340/5a576fcb9edb/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20dd/8971340/22bbe27a52c6/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20dd/8971340/2ce116307005/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20dd/8971340/9bd2ad9da859/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20dd/8971340/a52bb17366a0/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20dd/8971340/5a576fcb9edb/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20dd/8971340/22bbe27a52c6/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20dd/8971340/2ce116307005/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20dd/8971340/9bd2ad9da859/gr4.jpg

相似文献

1
Hypoxia-directed tumor targeting of CRISPR-Cas9 and HSV-TK suicide gene therapy using lipid nanoparticles.利用脂质纳米颗粒进行CRISPR-Cas9和单纯疱疹病毒胸苷激酶自杀基因疗法的缺氧导向肿瘤靶向治疗。
Mol Ther Methods Clin Dev. 2022 Mar 16;25:158-169. doi: 10.1016/j.omtm.2022.03.008. eCollection 2022 Jun 9.
2
[Hypoxia responsive element regulated herpes simplex virus-thymidine kinase system enhances killing effect of gancyclovir on Ewing's sarcoma cell line under hypoxic condition].[缺氧反应元件调控的单纯疱疹病毒胸苷激酶系统增强更昔洛韦在缺氧条件下对尤因肉瘤细胞系的杀伤作用]
Zhonghua Er Ke Za Zhi. 2006 Aug;44(8):616-20.
3
Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells.血管内皮生长因子基因启动子驱动的自杀基因对缺氧肿瘤细胞的治疗效果。
Cancer Res. 2000 Jun 1;60(11):2936-41.
4
[HSV-TK gene therapy of lung adenocarcinoma xenografts using a hypoxia/radiation dual-sensitive promoter].[使用缺氧/辐射双敏感启动子的肺腺癌异种移植瘤单纯疱疹病毒胸苷激酶基因治疗]
Ai Zheng. 2004 Jul;23(7):788-93.
5
Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo.腺病毒介导的缺氧靶向基因治疗,使用单纯疱疹病毒胸苷激酶和细菌硝基还原酶前药激活基因,在体外和体内。
Cancer Gene Ther. 2011 Nov;18(11):773-84. doi: 10.1038/cgt.2011.43. Epub 2011 Aug 12.
6
Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells.生成双向缺氧/HIF反应性表达载体以将基因表达靶向缺氧细胞。
Gene Ther. 2001 Dec;8(23):1801-7. doi: 10.1038/sj.gt.3301605.
7
[Construction and identification of recombinant vectors carrying herpes simplex virus thymidine kinase genes expressed in vascular endothelial cells].[携带在血管内皮细胞中表达的单纯疱疹病毒胸苷激酶基因的重组载体的构建与鉴定]
Ai Zheng. 2006 Feb;25(2):179-84.
8
STAT3/NF-κB-Regulated Lentiviral TK/GCV Suicide Gene Therapy for Cisplatin-Resistant Triple-Negative Breast Cancer.STAT3/NF-κB调控的慢病毒TK/GCV自杀基因疗法治疗顺铂耐药三阴性乳腺癌
Theranostics. 2017 Jan 15;7(3):647-663. doi: 10.7150/thno.16827. eCollection 2017.
9
Herpes simplex virus amplicon delivery of a hypoxia-inducible soluble vascular endothelial growth factor receptor (sFlk-1) inhibits angiogenesis and tumor growth in pancreatic adenocarcinoma.单纯疱疹病毒扩增子递送缺氧诱导型可溶性血管内皮生长因子受体(sFlk-1)可抑制胰腺腺癌中的血管生成和肿瘤生长。
Ann Surg Oncol. 2005 Dec;12(12):1025-36. doi: 10.1245/ASO.2005.03.081. Epub 2005 Oct 25.
10
Cancer-specific targeting of an adenovirus-delivered herpes simplex virus thymidine kinase suicide gene using translational control.利用翻译控制对腺病毒递送的单纯疱疹病毒胸苷激酶自杀基因进行癌症特异性靶向。
J Gene Med. 2006 Sep;8(9):1105-20. doi: 10.1002/jgm.935.

引用本文的文献

1
Emerging Gene-editing nano-therapeutics for Cancer.新兴的用于癌症治疗的基因编辑纳米疗法
Heliyon. 2024 Oct 20;10(21):e39323. doi: 10.1016/j.heliyon.2024.e39323. eCollection 2024 Nov 15.
2
Microneedle-mediated nanomedicine to enhance therapeutic and diagnostic efficacy.微针介导的纳米药物以提高治疗和诊断效果。
Nano Converg. 2024 Apr 18;11(1):15. doi: 10.1186/s40580-024-00421-w.
3
Design of hypoxia responsive CRISPR-Cas9 for target gene regulation.缺氧响应型 CRISPR-Cas9 设计用于靶基因调控。

本文引用的文献

1
Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment.基于EPR效应的肿瘤靶向治疗癌症的最新进展
J Pers Med. 2021 Jun 18;11(6):571. doi: 10.3390/jpm11060571.
2
Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors.缺氧感应 CAR T 细胞为实体瘤治疗提供了安全性和疗效。
Cell Rep Med. 2021 Apr 9;2(4):100227. doi: 10.1016/j.xcrm.2021.100227. eCollection 2021 Apr 20.
3
Systemic delivery of CRISPR/Cas9 to hepatic tumors for cancer treatment using altered tropism of lentiviral vector.利用慢病毒载体改变的嗜性实现 CRISPR/Cas9 系统递送至肝肿瘤用于癌症治疗。
Sci Rep. 2023 Oct 5;13(1):16763. doi: 10.1038/s41598-023-43711-9.
4
Recent Advances in Nanomaterials-Based Targeted Drug Delivery for Preclinical Cancer Diagnosis and Therapeutics.基于纳米材料的靶向药物递送在临床前癌症诊断与治疗中的最新进展
Bioengineering (Basel). 2023 Jun 25;10(7):760. doi: 10.3390/bioengineering10070760.
5
Genome editing and cancer therapy: handling the hypoxia-responsive pathway as a promising strategy.基因组编辑与癌症治疗:以缺氧反应通路为靶点的治疗策略
Cell Mol Life Sci. 2023 Jul 21;80(8):220. doi: 10.1007/s00018-023-04852-2.
6
CRISISS: A Novel, Transcriptionally and Post-Translationally Inducible CRISPR/Cas9-Based Cellular Suicide Switch.CRISISS:一种新型的、转录后诱导型 CRISPR/Cas9 基于的细胞自杀开关。
Int J Mol Sci. 2023 Jun 6;24(12):9799. doi: 10.3390/ijms24129799.
7
Adipose Tissue-Derived Extracellular Vesicles Contribute to Phenotypic Plasticity of Prostate Cancer Cells.脂肪组织衍生的细胞外囊泡促进前列腺癌细胞的表型可塑性。
Int J Mol Sci. 2023 Jan 8;24(2):1229. doi: 10.3390/ijms24021229.
8
Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer.新兴纳米技术治疗药物对抗多药耐药性癌症。
J Nanobiotechnology. 2022 Sep 24;20(1):423. doi: 10.1186/s12951-022-01626-z.
9
From Immunotoxins to Suicide Toxin Delivery Approaches: Is There a Clinical Opportunity?从免疫毒素到自杀毒素递药方法:是否存在临床机会?
Toxins (Basel). 2022 Aug 23;14(9):579. doi: 10.3390/toxins14090579.
10
The Contribution of the Minimal Promoter Element to the Activity of Synthetic Promoters Mediating CAR Expression in the Tumor Microenvironment.最小启动子元件对介导 CAR 表达的合成启动子在肿瘤微环境中的活性的贡献。
Int J Mol Sci. 2022 Jul 4;23(13):7431. doi: 10.3390/ijms23137431.
Biomaterials. 2021 May;272:120793. doi: 10.1016/j.biomaterials.2021.120793. Epub 2021 Apr 1.
4
Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.临床认可基于纳米技术的 SARS-CoV-2 mRNA 疫苗:对转化纳米医学的影响。
Drug Deliv Transl Res. 2021 Aug;11(4):1309-1315. doi: 10.1007/s13346-021-00911-y. Epub 2021 Jan 29.
5
Engineering precision nanoparticles for drug delivery.工程化精准纳米颗粒用于药物递送。
Nat Rev Drug Discov. 2021 Feb;20(2):101-124. doi: 10.1038/s41573-020-0090-8. Epub 2020 Dec 4.
6
Amplification-free long-read sequencing reveals unforeseen CRISPR-Cas9 off-target activity.无扩增长读测序揭示了意想不到的 CRISPR-Cas9 脱靶活性。
Genome Biol. 2020 Dec 1;21(1):290. doi: 10.1186/s13059-020-02206-w.
7
CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy.利用靶向脂质纳米粒进行 CRISPR-Cas9 基因组编辑治疗癌症。
Sci Adv. 2020 Nov 18;6(47). doi: 10.1126/sciadv.abc9450. Print 2020 Nov.
8
Hypoxia and its therapeutic possibilities in paediatric cancers.缺氧及其在儿科癌症治疗中的可能性。
Br J Cancer. 2021 Feb;124(3):539-551. doi: 10.1038/s41416-020-01107-w. Epub 2020 Oct 27.
9
Conditionally Replicating Vectors Mobilize Chimeric Antigen Receptors against HIV.条件性复制载体动员嵌合抗原受体对抗HIV。
Mol Ther Methods Clin Dev. 2020 Sep 28;19:285-294. doi: 10.1016/j.omtm.2020.09.014. eCollection 2020 Dec 11.
10
A Versatile Nonviral Delivery System for Multiplex Gene-Editing in the Liver.一种多功能非病毒递药系统,用于肝脏的多重基因编辑。
Adv Mater. 2020 Nov;32(46):e2003537. doi: 10.1002/adma.202003537. Epub 2020 Oct 14.